These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 14967451)

  • 1. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies.
    Viloria-Petit AM; Kerbel RS
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):914-26. PubMed ID: 14967451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
    Bianco R; Troiani T; Tortora G; Ciardiello F
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
    Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
    Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
    Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
    Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
    Raben D; Helfrich B; Bunn PA
    Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs.
    Arteaga CL
    J Clin Oncol; 2003 Dec; 21(23 Suppl):289s-291s. PubMed ID: 14645415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors.
    Sartor CI
    Nat Clin Pract Oncol; 2004 Dec; 1(2):80-7. PubMed ID: 16264825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J
    Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
    Cohenuram M; Saif MW
    JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy.
    Ang KK; Andratschke NH; Milas L
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):959-65. PubMed ID: 14967456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress?
    Raben D; Bianco C; Milas L; Ang KK
    Semin Radiat Oncol; 2004 Apr; 14(2):139-52. PubMed ID: 15095260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stepwise progress in epidermal growth factor receptor/radiation studies for head and neck cancer.
    Harari PM
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S25-7. PubMed ID: 17848286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors.
    Krause M; Gurtner K; Deuse Y; Baumann M
    Int J Radiat Biol; 2009 Nov; 85(11):943-54. PubMed ID: 19895271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.